search
Back to results

RGS@Home: Personalized 24/7 Home Care Post-stroke

Primary Purpose

Hemiparesis;Poststroke/CVA, Stroke, Acute, Motor Disorders

Status
Recruiting
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
RGS based training and monitoring
Therapy as usual
Sponsored by
Institute for Bioengineering of Catalonia
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hemiparesis;Poststroke/CVA

Eligibility Criteria

20 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria:

  • Patients presenting a first-ever ischemic or intracerebral hemorrhagic stroke.
  • A CT SCAN and/or MRI had exclude other pathologies.
  • Lesion localization by clinical symptoms/signs.
  • Moderate to mild proximal upper limb motor impairment (MRC≥2).
  • Age 20-85 years old.
  • Able to sit on a chair or a wheelchair interacting with the RGS during a full session, and be capable and willing to participate in RGS therapy.

Exclusion criteria:

  • Presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the patient or the quality of the data.
  • Severe cognitive capabilities that prevent the execution of the experiment (MoCA < 19). This cut-off score is based on pilot study (Maier, M. et al, 2019).
  • Arteriovenous malformation or lesions not related with a stroke.
  • Severe associated impairment such as spasticity, communication disabilities (sensorial, Wernicke aphasia or apraxia), major pain or other neuromuscular impairments or orthopedic devices that would interfere with the correct execution of the experiment (Modified Ashworth Scale < 3).
  • Unable to use the RGS independently according to the therapist's observations and lacking support from a caregiver to use the RGS.
  • Refusal to sign the consent form.
  • Pre-stroke history of upper limb motor disability.

Sites / Locations

  • Institute for Bioengineering of Catalonia - Specs LabRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

RGS based therapy

Treatment as usual

Arm Description

Outcomes

Primary Outcome Measures

Change in the score of the upper extremity section of the Fugl-Meyer Assessment Test [min=0, max=66]. Higher scores indicate better functioning.
Change in score from baseline to end of treatment (12 weeks).

Secondary Outcome Measures

Change in Barthel Index [min=0, max=100]. Higher scores indicate better functioning.
Change in score from baseline to end of treatment (12 weeks).
Change in Barthel Index [min=0, max=100]. Higher scores indicate better functioning.
Change in score from baseline to end of treatment (12 months).
Number of patients that are readmitted into the hospital (inpatient) after being discharged to at-home status.
Number of patients from baseline to 12 months post-baseline.
Change in the Stroke Specific Quality Of Life scale (SS-QOL) [min=49, max=245]. Higher scores indicate better functioning.
Change in score from baseline to end of treatment (12 weeks).
Change in the Stroke Specific Quality Of Life scale (SS-QOL) [min=49, max=245]. Higher scores indicate better functioning.
Change in score from baseline to follow-up (12 months).
Change in the SIS (Stroke impact Scale) [min=0, max=42]. Higher scores indicate better functioning.
Change in score from baseline to end of treatment (12 weeks).
Change in the SIS (Stroke impact Scale) [min=0, max=42]. Higher scores indicate better functioning.
Change in score from baseline to follow-up (12 months).
Change in the Hamilton Scale Depression [min=0, max=52]. Lower scores indicate less impairment.
Change in score from baseline to end of treatment (12 weeks).
Change in the Hamilton Scale Depression [min=0, max=52]. Lower scores indicate less impairment.
Change in score from baseline to follow-up (12 months).
Change in the Visual Analogue Score (VAS) [min=0, max=10]. Lower scores indicate less impairment.
Change in score from baseline to end of treatment (12 weeks).
Change in the Ashworth Scale [min=0, max=4]. Lower scores indicate less impairment.
Change in score from baseline to follow-up (12 months).
Change in the Fatigue Severity Scale [min=9, max=63]. Higher scores indicate more fatigue.
Change in score from baseline to end of treatment (12 weeks).
Change in the Fatigue Severity Scale [min=9, max=63]. Higher scores indicate more fatigue.
Change in score from baseline to follow-up (12 months).
Change in the Wellbeing questionnaire (SF-36) [min=0, max=100]. Higher scores indicate more wellbeing.
Change in score from baseline to end of treatment (12 weeks).
Change in the Wellbeing questionnaire (SF-36) [min=0, max=100]. Higher scores indicate more wellbeing.
Change in score from baseline to follow-up (12 months).
Change in the score of the upper extremity section of the Fugl-Meyer Assessment Test. [min=0, max=66]. Higher scores indicate better functioning.
Change in score from baseline to follow-up (12 months).

Full Information

First Posted
November 3, 2020
Last Updated
November 16, 2021
Sponsor
Institute for Bioengineering of Catalonia
search

1. Study Identification

Unique Protocol Identification Number
NCT04620707
Brief Title
RGS@Home: Personalized 24/7 Home Care Post-stroke
Official Title
RGS@Home Project: Scaling ICT Based Neurorehabilitation to Personalized 24/7 Home Care Post-stroke
Study Type
Interventional

2. Study Status

Record Verification Date
November 2021
Overall Recruitment Status
Recruiting
Study Start Date
November 9, 2020 (Actual)
Primary Completion Date
July 1, 2022 (Anticipated)
Study Completion Date
July 1, 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Institute for Bioengineering of Catalonia

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Stroke represents one of the main causes of adult disability and will be one of the main contributors to the burden of disease in 2030. However, the healthcare systems are not able to respond to the current demand let alone its future increase. There is a need to deploy new approaches that advance current rehabilitation methods and enhance their efficiency. One of the latest approaches used for the rehabilitation of a wide range of deficits of the nervous system is based on virtual reality (VR) applications, which combine training scenarios with dedicated interface devices. Market drivers exist for new ICT based treatment solutions. IBEC/ Eodyne Systems has developed and commercialised the Rehabilitation Gaming System (RGS), a science-based ICT solution for neurorehabilitation combining brain theory, AI, cloud computing and virtual reality and targeting motor and cognitive recovery after stroke. RGS provides a continuum of evaluations and therapeutic solutions that accompany the patient from the clinic to the therapy centre. RGS has been clinically validated showing its superiority over other products while reducing cost also through its use of standard off-the-shelf hardware and a Software as a Service model (SaaS). Commercial evaluations have shown that RGS acts as a workforce multiplier while delivering a high quality of care at clinical centres (RGS@Clinic). However, in order to achieve significant benefits in the patients' QoL, it is essential that RGS becomes an at home solution providing 24/7 monitoring and care. For this reason, this project aims at investigating the RGS acceptability and adoption model. The findings derived from this study will contribute to establish a novel and superior neurorehabilitation paradigm that can accelerate the recovery of hemiparetic stroke patients. Besides the clinical impact, such achievement could have relevant socioeconomic impact.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hemiparesis;Poststroke/CVA, Stroke, Acute, Motor Disorders, Spasticity, Muscle

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
90 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
RGS based therapy
Arm Type
Experimental
Arm Title
Treatment as usual
Arm Type
Active Comparator
Intervention Type
Device
Intervention Name(s)
RGS based training and monitoring
Intervention Description
The RGS treatment will consist in a variable number of sessions per week of RGS-based training. Each session consists of cognitive and motor training involving reaching, grasping, placing virtual objects. The duration of the training period will be variable. Patients will use the RGS@Clinic from admission to discharge, and will have the RGS@Home during the first 3 months of the outpatient stage after recruitment. After this period of time, the patient will be evaluated by clinicians and the RGS@Home system will be collected. The RGS-Wear will be kept by the patient also during the follow-up period, up to 1 year post-recruitment.
Intervention Type
Behavioral
Intervention Name(s)
Therapy as usual
Intervention Description
The patients will follow treatment as usual, including conventional rehabilitation and physical therapy when corresponding. The exact treatment that the patients will receive will depend on the local medical guidelines.
Primary Outcome Measure Information:
Title
Change in the score of the upper extremity section of the Fugl-Meyer Assessment Test [min=0, max=66]. Higher scores indicate better functioning.
Description
Change in score from baseline to end of treatment (12 weeks).
Time Frame
12 weeks.
Secondary Outcome Measure Information:
Title
Change in Barthel Index [min=0, max=100]. Higher scores indicate better functioning.
Description
Change in score from baseline to end of treatment (12 weeks).
Time Frame
12 weeks.
Title
Change in Barthel Index [min=0, max=100]. Higher scores indicate better functioning.
Description
Change in score from baseline to end of treatment (12 months).
Time Frame
12 months.
Title
Number of patients that are readmitted into the hospital (inpatient) after being discharged to at-home status.
Description
Number of patients from baseline to 12 months post-baseline.
Time Frame
12 months.
Title
Change in the Stroke Specific Quality Of Life scale (SS-QOL) [min=49, max=245]. Higher scores indicate better functioning.
Description
Change in score from baseline to end of treatment (12 weeks).
Time Frame
12 weeks.
Title
Change in the Stroke Specific Quality Of Life scale (SS-QOL) [min=49, max=245]. Higher scores indicate better functioning.
Description
Change in score from baseline to follow-up (12 months).
Time Frame
12 months.
Title
Change in the SIS (Stroke impact Scale) [min=0, max=42]. Higher scores indicate better functioning.
Description
Change in score from baseline to end of treatment (12 weeks).
Time Frame
12 weeks.
Title
Change in the SIS (Stroke impact Scale) [min=0, max=42]. Higher scores indicate better functioning.
Description
Change in score from baseline to follow-up (12 months).
Time Frame
12 months.
Title
Change in the Hamilton Scale Depression [min=0, max=52]. Lower scores indicate less impairment.
Description
Change in score from baseline to end of treatment (12 weeks).
Time Frame
12 weeks.
Title
Change in the Hamilton Scale Depression [min=0, max=52]. Lower scores indicate less impairment.
Description
Change in score from baseline to follow-up (12 months).
Time Frame
12 months.
Title
Change in the Visual Analogue Score (VAS) [min=0, max=10]. Lower scores indicate less impairment.
Description
Change in score from baseline to end of treatment (12 weeks).
Time Frame
12 weeks.
Title
Change in the Ashworth Scale [min=0, max=4]. Lower scores indicate less impairment.
Description
Change in score from baseline to follow-up (12 months).
Time Frame
12 months.
Title
Change in the Fatigue Severity Scale [min=9, max=63]. Higher scores indicate more fatigue.
Description
Change in score from baseline to end of treatment (12 weeks).
Time Frame
12 weeks.
Title
Change in the Fatigue Severity Scale [min=9, max=63]. Higher scores indicate more fatigue.
Description
Change in score from baseline to follow-up (12 months).
Time Frame
12 months.
Title
Change in the Wellbeing questionnaire (SF-36) [min=0, max=100]. Higher scores indicate more wellbeing.
Description
Change in score from baseline to end of treatment (12 weeks).
Time Frame
12 weeks.
Title
Change in the Wellbeing questionnaire (SF-36) [min=0, max=100]. Higher scores indicate more wellbeing.
Description
Change in score from baseline to follow-up (12 months).
Time Frame
12 months.
Title
Change in the score of the upper extremity section of the Fugl-Meyer Assessment Test. [min=0, max=66]. Higher scores indicate better functioning.
Description
Change in score from baseline to follow-up (12 months).
Time Frame
12 months.
Other Pre-specified Outcome Measures:
Title
Number of falls reported by the participants.
Time Frame
12 weeks.
Title
Number of falls reported by the participants.
Time Frame
12 months.
Title
Change in Barthel Index [min=0, max=100]. Higher scores indicate better functioning.
Description
Change in score from baseline to follow-up (6 months).
Time Frame
6 months.
Title
Change in the stroke specific Quality of Life scale (SS-QOL) [min=49, max=245]. Higher scores indicate better functioning.
Description
Change in score from baseline to follow-up (6 months).
Time Frame
6 months.
Title
Change in the Wellbeing questionnaire (SF-36) [min=0, max=100]. Higher scores indicate more wellbeing.
Description
Change in score from baseline to follow-up (6 months).
Time Frame
6 months.
Title
Change in the score of the upper extremity section of the Fugl-Meyer Assessment Test [min=0, max=66]. Higher scores indicate better functioning.
Description
Change in score from baseline to follow-up (6 months).
Time Frame
6 months.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria: Patients presenting a first-ever ischemic or intracerebral hemorrhagic stroke. A CT SCAN and/or MRI had exclude other pathologies. Lesion localization by clinical symptoms/signs. Moderate to mild proximal upper limb motor impairment (MRC≥2). Age 20-85 years old. Able to sit on a chair or a wheelchair interacting with the RGS during a full session, and be capable and willing to participate in RGS therapy. Exclusion criteria: Presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the patient or the quality of the data. Severe cognitive capabilities that prevent the execution of the experiment (MoCA < 19). This cut-off score is based on pilot study (Maier, M. et al, 2019). Arteriovenous malformation or lesions not related with a stroke. Severe associated impairment such as spasticity, communication disabilities (sensorial, Wernicke aphasia or apraxia), major pain or other neuromuscular impairments or orthopedic devices that would interfere with the correct execution of the experiment (Modified Ashworth Scale < 3). Unable to use the RGS independently according to the therapist's observations and lacking support from a caregiver to use the RGS. Refusal to sign the consent form. Pre-stroke history of upper limb motor disability.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Paul Verschure, PhD
Phone
+34934011918
Email
paul.verschure@specs-lab.com
Facility Information:
Facility Name
Institute for Bioengineering of Catalonia - Specs Lab
City
Barcelona
ZIP/Postal Code
08930
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Paul Verschure

12. IPD Sharing Statement

Citations:
PubMed Identifier
35725616
Citation
Mura A, Maier M, Ballester BR, De la Torre Costa J, Lopez-Luque J, Gelineau A, Mandigout S, Ghatan PH, Fiorillo R, Antenucci F, Coolen T, Chivite I, Callen A, Landais H, Gomez OI, Melero C, Brandi S, Domenech M, Daviet JC, Zucca R, Verschure PFMJ. Bringing rehabilitation home with an e-health platform to treat stroke patients: study protocol of a randomized clinical trial (RGS@home). Trials. 2022 Jun 20;23(1):518. doi: 10.1186/s13063-022-06444-0.
Results Reference
derived

Learn more about this trial

RGS@Home: Personalized 24/7 Home Care Post-stroke

We'll reach out to this number within 24 hrs